Updates to the recommendations, tables, treatment algorithms, and/or guideline text in this publication are made with the approval of the SITC Cancer Immunotherapy Guideline Expert Panel. More information on the SITC Guidelines can be found at sitcancer.org/guidelines

Update October 2022

In response to recent data regarding increased risk for MACE in patients with RCC receiving ICI + VEGF TKI therapy, the ICI-related Adverse Events Guideline was updated in the following location: * General Expert Panel Recommendations

Reference: Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

Update 8-7-2021

To add additional guidance on the management of patients with ICI-related hypophysitis and severe compressive symptoms, the ICI-related Adverse Events CPG was updated in the following location: * Endocrine Toxicity Expert Panel Recommendations

Update 8-27-2021

To add additional guidance on the management of patients with ICI-related hypophysitis and severe compressive symptoms, this recommendation was updated, as noted below:

• Patients with hypophysitis should receive replacement hydrocortisone at 10–12 mg/m2/day; a short-course of prednisone 1mg/kg (or equivalent) may be given for patients with severe compressive symptoms (e.g. headache, double vision).

Update October 2022

The recommendation on baseline troponin testing has been updated, as noted below:

• Consider performing a baseline electrocardiogram (EKG) and baseline troponin testing on patients deemed at a higher risk for myocarditis (eg, cardiac comorbidities, diabetes mellitus, ICI combination regimens including dual ICIs or VEGF TKIs, etc). Patients receiving ICI plus VEGF TKIs who have elevated baseline troponin T should be closely monitored for major cardiac adverse events.